1. Home
  2. CBRL vs SLN Comparison

CBRL vs SLN Comparison

Compare CBRL & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cracker Barrel Old Country Store Inc

CBRL

Cracker Barrel Old Country Store Inc

SELL

Current Price

$69.60

Market Cap

1.5B

ML Signal

SELL

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

SELL

Current Price

$19.81

Market Cap

1.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CBRL
SLN
Founded
1969
1994
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
1998
2010

Fundamental Metrics

Financial Performance
Metric
CBRL
SLN
Price
$69.60
$19.81
Analyst Decision
Hold
Hold
Analyst Count
9
5
Target Price
★ $50.71
$19.75
AVG Volume (30 Days)
643.2K
★ 4.2M
Earning Date
12-08-2026
11-12-2026
Dividend Yield
★ 1.47%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 1.40
N/A
Revenue
★ $3,030,445,000.00
$559,000.00
Revenue This Year
$1.72
N/A
Revenue Next Year
$2.28
$174.87
P/E Ratio
$48.54
★ N/A
Revenue Growth
★ 3.56
N/A
52 Week Low
$24.85
$4.19
52 Week High
$73.67
$19.87

Technical Indicators

Market Signals
Indicator
CBRL
SLN
Relative Strength Index (RSI) 59.83 77.58
Support Level $28.43 $19.70
Resistance Level $70.28 $19.87
Average True Range (ATR) 2.85 0.06
MACD -0.53 -0.27
Stochastic Oscillator 61.31 64.52

Price Performance

Historical Comparison
CBRL
SLN

About CBRL Cracker Barrel Old Country Store Inc

Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants menu that features home-style country food and a wide variety of decorative and functional items such as rocking chairs, holiday and seasonal gifts, toys, apparel, cookware and foods.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: